These findings show that targeting the IL-6/JAK/STAT pathway to suppress the autocrine and paracrine effects of IL-6, as well as its classical signaling and trans-signaling, is the preferred therapy strategy for DKD (Figure 2). This evidence concerns the gene SOAT1 and diabetic kidney disease.